Dosimetric Comparison of CPAP and DIBH for Left-sided Breast Cancer Radiation Therapy

Purpose: Despite the increasing interest in using continuous positive airway pressure (CPAP) in radiation therapy (RT), direct comparisons with the more widely used deep inspiration breath-hold (DIBH) have been limited. This planning study aimed to offer comprehensive geometric and dosimetric evidence by comparing CPAP and DIBH-based RT plans. Materials and Methods: A retrospective data set of 35 patients with left-sided breast cancer with planning computed tomography scans under three breathing conditions (freee breathing (FB), CPAP with 10 cmH2O 2 O pressure, and DIBH) was collected. Volumetric arc therapy plans aimed for 95% dose coverage to 95% of the planning target volume with a maximum dose below 107%. A comparative dosimetric analysis among the three plans was conducted. Additionally, geometric differences were assessed by calculating the minimum distance between the heart and the clinical target volume (CTV) in each planning computed tomography. Results: CPAP and DIBH plans demonstrated comparable mean heart doses (1.05 Gy), which were significantly fi cantly lower than the FB plan (1.34 Gy). The maximum dose to the left anterior descending artery was smallest in the CPAP plan (4.44 Gy), followed by DIBH (4.73 Gy) and FB (7.33 Gy) plans. Other organ-at-risk doses for CPAP and DIBH were similar, with mean contralateral breast doses of 2.27 and 2.21 Gy, mean ipsilateral lung doses of 4.09 and 4.08 Gy, V20 at 6.11% and 6.31%, and mean contralateral lung doses of 0.94 and 0.92 Gy, respectively. No significant fi cant difference was found in the minimum heart-to-CTV distance between CPAP and DIBH. DIBH exhibited the greatest lung volume (3908 cc), followed by CPAP (3509 cc), and FB(2703 cc). Conclusions: The comparison between CPAP and DIBH shows their similarity in both geometric and dosimetric aspects, providing strong evidence for CPAP's ' s effectiveness and feasibility in RT. This suggests its potential as an alternative to DIBH for patients with left-sided breast cancer.